Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06973681) titled 'A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects' on May 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Condition:
Overweight or Obesity
Intervention:
Drug: BGM0504
Drug: BGM0504
Drug: BGM0504
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 13, 2023
Target Sample Size: 120
Countries of Recruitment:
China
To know more, visit https://clinicalt...